The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors
Open accessThe DOI matches its Crossref record; 229 of the 231 references it cites were found in a registry or an index; 136 of the 207 sources its claims cite were checked for support.
Abstract
The ideal in vitro recreation of the micro-tumor niche-although much needed for a better understanding of cancer etiology and development of better anticancer therapies-is highly challenging. Tumors are complex three-dimensional (3D) tissues that establish a dynamic cross-talk with the surrounding tissues through complex chemical signaling. An extensive body of experimental evidence has established that 3D culture systems more closely recapitulate the architecture and the physiology of human solid tumors when compared with traditional 2D systems. Moreover, conventional 3D culture systems fail to recreate the dynamics of the tumor niche. Tumor-on-chip systems, which are microfluidic devices that aim to recreate relevant features of the tumor physiology, have recently emerged as powerful tools in cancer research. In tumor-on-chip systems, the use of microfluidics adds another dimension of physiological mimicry by allowing a continuous feed of nutrients (and pharmaceutical compounds). Here, we discuss recently published literature related to the culture of solid tumor-like tissues in microfluidic systems (tumor-on-chip devices). Our aim is to provide the readers with an overview of the state of the art on this particular theme and to illustrate the toolbox available today for engineering tumor-like structures (and their environments) in microfluidic devices. The suitability of tumor-on-chip devices is increasing in many areas of cancer research, including the study of the physiology of solid tumors, the screening of novel anticancer pharmaceutical compounds before resourcing to animal models, and the development of personalized treatments. In the years to come, additive manufacturing (3D bioprinting and 3D printing), computational fluid dynamics, and medium- to high-throughput omics will become powerful enablers of a new wave of more sophisticated and effective tumor-on-chip devices.
Overview
CoChat Summary
## TL;DR
This is a tutorial review of tumor-on-chip systems for solid-tumor research, arguing that microfluidic 3D models better recapitulate tumor physiology and dynamics than traditional 2D culture and many animal or static 3D models. It surveys recent device architectures and applications, especially spheroid models, co-cultures with stromal/healthy cells, vascularized chips, drug screening, nanoparticle transport, and precision-medicine uses.
## Key findings
- The paper states that less than 10% of anticancer drugs entering clinical trials reach the market, motivating more predictive preclinical models.
- Tumor-on-chip systems are presented as better than 2D culture because they can incorporate 3D architecture, dynamic flow, nutrients, and pharmaceutical compounds, and as more controllable than animal models, which are described as time-, resource-, and expertise-intensive and not fully human-relevant.
- In a 48-h perfused mesothelioma spheroid chip, spheroid morphology stayed essentially unchanged, but perfused spheroids showed higher chemoresistance to cisplatin than static spheroids; the system used about 5000 cells per assay.
- Several examples reported quantitative treatment or transport effects, including 100 nm nanoparticles penetrating better than 200 nm particles, DOX at 10 and 100 µg/mL destroying an endothelial barrier in one co-culture model, vessels in breast tumor compartments being 2.62-fold more permeable to nanoparticles than healthy-tissue vessels, and vascularized HCT116 microtumors showing one-order-higher chemoresistance to oxaliplatin than 2D monolayers.
## Methods
- Design: Narrative/tutorial review organized by increasing model complexity: simple spheroids, spheroids in hydrogels, non-spheroid cancer–normal co-cultures, vascularized systems, and precision-medicine applications.
- Data/sample: The review focuses on recent literature from 2011 onward on solid-tumor microfluidic systems and cites multiple representative device studies and model systems.
- Analysis: Comparative synthesis of published examples, emphasizing device architecture, fabrication/materials, flow and pressure control, and reported biological readouts such as drug response, nanoparticle transport, cell invasion, and vascular permeability.
## Limitations
- The paper states that the complete recapitulation of the true nature and evolution of a malignant tumor in vitro is challenging, and that high-fidelity 3D emulation remains an aspiration.
- It states that microfluidic device fabrication still requires skill and experience, and that better biomaterials, 3D printing, CFD, and omics will be needed for more advanced systems.
- Evident from the text: this is a review, not an original experimental study, so its conclusions depend on the quality and scope of the cited literature rather than new primary data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Recapitulation of the tumor niche using tumor-on-chip systems with various degrees of sophistication. (a) The evolution of our cancer research tools—from 2D to 3D, and beyond—tumor-on-chip systems. Colored circles show the degree of fulfillment of different features. Green: fully fulfilled; Yellow: partially fulfilled; Red: poorly fulfilled; (b) Scheme of the tumor niche. Modified from Han et al., 2016 [19]. (c) Different types of tumor-on-chip systems: from simple spheroids in a microflow to vascularized and perfusable tumor microtissues [20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72].](https://figures.cochat.ai/paper-figures/c26bbf874804474397dc5dfe2bb673c9/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-1.jpg)
![Figure 2 Architecture of tumor spheroids and their fabrication techniques. (a) Schematic representation of the 3D architecture of a tumor spheroid. Modified from Sant and Johnston 2017 [126]; (b) Fabrication of spheroids by the following scaffold-free methods: (i) hanging drop [122,127,128,129], (ii) liquid-overlay method [130,131,132,133,134,135,136], and (iii) force-driven method [129,132,137,138,139,140,141]; (c) Fabrication of spheroids by the following scaffold-based methods: (i) spheroids with a matrix-on top and embedded in a matrix [133,134,135], (ii) spheroids encapsulated within a molded matrix [142,143,144], and (iii) spheroids formed by suspending cancer cells within a liquid matrix and applying microfluidic-based strategies to form spheroids in droplets [119,145,146,147,148].](https://figures.cochat.ai/paper-figures/e54332efbd5643e0917a359371e47974/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-2.jpg)
![Figure 3 Simple tumor-on-chip systems: a tumor spheroid continuously perfused within a microfluidic device. (a) Simple serpentine-shaped microfluidic system designed by Ruppen et al. [20], (i) designed to trap cancer cell agglomerates for fabrication of tumor spheroids. A simple hydraulic system enabled the trapping of cell agglomerates (scale bar: 10 μm) (ii) in small cavities. Once the upstream cavities were occupied by spheroids, flow was directed to downstream portions of the serpentine (scale bar: 500 μm) (iii) to favor new trapping events. (iv) Spheroids grew and matured in these cavities and were continuously exposed to anticancer compounds. Taken from reference [20]; (b) Microfluidic device developed by Huang et al. [21]: (i) general architecture, (ii) hydraulic testing, (iii) detail of the spheroid traps, and (iv) actual spheroid trapped in a holder as imaged in bright field. Schematic representation of the effect of (scale bar: 50 μm) (v) protein corona, and (vi) charge, on nanoparticle penetration into tumor spheroids. Taken from reference [21]; (c) Simple pump-independent (i) microfluidic system devised by Patra et al. [22] for continuous formation and perfusion of cancer spheroids (ii) contained within rectangular cavities located at the floor of the microfluidic circuit. (iii) Flow is driven simply by a pressure head induced by a difference in the height of the column of liquid (culture medium) between the inlet and the outlet reservoir. Taken from reference [22]; (d) Tumor-on-chip system developed by Chen et al. [177]: (i) Scheme of the physiological context aimed, (ii) and overall microfluidic architecture. (iii) 3D-render showing cancer cells retained within a horseshoe trap. Red and blue arrows indicate the flow fields within the system. (iv) Scheme of the architecture of the system (side view), (v) detail of the array of traps holding spheroids of consistent size, and (vi) size of spheroids after 14 days of culture. Scale bar: 200 μm. Taken from reference [177]; (e) The microfluidic system developed by Lim and Park [23] enables the exposure of cancer spheroids to anticancer drug gradients. (i) Scheme of the overall architecture of the device, (ii) detail of the cell-culture section, and (iii) close-up showing the geometry of each culture microwell. (iv) Experimental demonstration of the effective generation of gradients using injections of a fluorescent tracer. Taken from reference [23].](https://figures.cochat.ai/paper-figures/7970a8152adf491395a936fa18311833/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-3.jpg)
![Figure 4 Tumor-on-chip in which a spheroid is embedded in a hydrogel. (a) Microfluidic system proposed by Albanese et al. [27]: (i) scheme of the optically accessible TOC, (ii) actual image of the spheroid within the microfluidic chamber (scale bar: 1000 μm). The tumor spheroid is lightly embedded in collagen. Scale bar: 100 μm. (iii) Interstitial volume exchange (residence time within a spheroid) as a function of the inlet flow rate (black squares); the corresponding interstitial flow rate is shown (red diamonds). (iv) Scheme and image of 40 nm PEG nanoparticles penetrating the spheroid and accumulating in the interstitial spaces (scale bar: 100 μm). (v) Larger nanoparticles (d = 110 nm) cannot penetrate the spheroid. Scale bar: 100 µm. (vi) Nanoparticle of different sizes [40 nm (red); 70 nm (blue); 110 (green), and 150 (blue)] exhibit different accumulation rates within spheroids. Nanoparticles were injected into the chamber at 50 mL/h; (b) The tumor on chip designed by Kwak et al. [28] aimed to recapitulate (i) the dynamics induced by the pressure gradient between the capillary and the lymphatic nets. (ii) Scheme (scale bar: 300 μm) and (iii) actual microdevice: cancer spheroids (indicated by arrows) develop within collagen in the central compartment by day 3. These spheroids, like actual tumors, express (iv) E-cadherin and (v) collagen IV. Scale bar: 50 µm. This system enables studies of accumulation of nanoparticles within tumors. (vi) Concentration of 100 nm particles at different distances of the capillary boundary (vii) Accumulation of nanoparticles as a function of matrix stiffness, (viii) interstitial pressure, and (ix) particles size. Taken from reference [28]; (c) TOC devised by Piotrowsky-Daspit [30] to study the effect of intra-tumor interstitial pressure on tumor invasiveness. (i) Schematic representation of the device; (ii) Micrographs showing an E-cadherin-GFP aggregate under a condition where the pressure gradient favors invasiveness (higher pressure at the tumor core). Modified from Piotrowsky-Daspit [30].](https://figures.cochat.ai/paper-figures/949525e8367d4789b57e35a88a0a5f66/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-4.jpg)
![Figure 5 Tumor-on-chip (TOC) systems in which cancerous and normal microtissues share an interface. (a) Crosstalk between cancer cells and fibroblasts in a Y-shaped TOC: (i) scheme and (ii) actual device. (iii) Human mammary fibroblasts (HMF) and breast cancer (MCF10-DCIS) cells establish a cross-talk at the interface between the cancerous and normal microtissue sections. Scale bar: 30 µm. (iv) Circularity, roundness, and aspect ratio (AR) of MCF10-DCIS cancer cells as a function of their distance from the interface. (v) Image analysis characterization of invasiveness. Taken from reference [33]; (b) On-chip activation of stromal tissue by crosstalk with cancerous tissue [35]: (i) schematic representation of the device and (ii) actual micrographs of normal cells (expressing GFP) and cancer cells (expressing RFP). Scale bar: 100 μm. (iii) Time sequence showing cancer cell migration and invasion. Scale bars: 100 μm; (c) TOC system that recapitulates early stage breast cancer: (i) tumor-niche aimed. (ii) Schematic representation of the TOC system. (iii) Cytotoxicity against cancerous DCIS spheroids and normal epithelial cells at different feeding conditions: continuous administration of Paclitaxel through the lower channel (open triangles), batch administration of paclitaxel on normal epithelial cells (open circles), and negative control (squares). (iv) Change in the projected area of a DCIS spheroid treated with paclitaxel in the TOC (white bars) and untreated (black bars; ** p < 0.05) (v) Micrographs of DCIS spheroids at day 0, after three days of culture, and after three days of paclitaxel treatment. Scale bars: 100 μm; (d) TOC by Ayuso et al. [36] to recapitulate hypoxia and nutrient gradients within cancerous tissue: (i) schematic representation and (ii) actual device. Scale bar: 1 cm. (iii) Evolution of the cancer cell viability profiles, and (iv-v) hypoxia levels within the device. Scale bar: 400 μm Taken from reference [36].](https://figures.cochat.ai/paper-figures/a5f48478b57c401495df89942ff126f5/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-5.jpg)
![Figure 6 Tumor-on-chip (TOC) systems that consider spheroids embedded in non-cancerous cell-laden-hydrogels. (a) Chemotaxis-driven assembly of endothelial barrier in a TOC platform [50]. Brightfield images of MCF7 spheroids co-cultured with human umbilical vein endothelial cells (HUVECs) (i) immediately after encapsulation, (ii) after three, and (iii) five days of culture. Scale bars: 200 μm. (iv) Evolution of HUVEC densities within different GelMA hydrogel zones 1 through 5 (zones are indicated on the oval inset). Zones are indicated within the inset. (v) Spheroid size as a function of culture time. Size was quantified as the projected area of the spheroid and normalized to its size at day 0; (*) and (**) indicate statistically significant differences of p < 0.05 and 0.01, respectively in a pairwise t-test. (vi) HUVECs and MCF7 spheroids (as observed in bright field) five (D5) and eight days (D8) after doxorubicin (DOX) treatment. Red arrows indicate the presence (or absence) of endothelial barrier. Scale Bar: 200 μm. (vii) MCF7 spheroid size after treatment with increasing doses of DOX. The spheroid area was normalized with respect to that of untreated spheroids. Significant differences are indicated by (*, **): p < 0.05 and 0.01, respectively (pair wise t-test). Taken from reference [50]; (b) TOC developed by Jeong et al. [51] to study the crosstalk and mutual activation between fibroblasts and cancer cells: (i) schematic of the device, (ii) and (iii) successive close-ups on the channel section, (iv) detail of the cell culture channel, and (iv) comparison of migration distances of fibroblasts in the direction of the cancerous region (blue) and the non-cancerous region (gray). (vi) Micrographs of cancer spheroids treated with different doses of DOX in monoculture and co-culture conditions. Scale bars: 50 μm. (vii) Evaluation of DOX efficacy in co-culture and monoculture conditions in this TOC. Significant differences are indicated by (*): p < 0.05. Taken from reference [51]; (c) TOC developed by Aref et al. [48], to model immune checkpoint blockade. (i) A real tumor is subjected to dissociation (mechanical and enzymatic) to yield dissociated tumor tissue (spheroids, cell agglomerates and single cells); (ii) schematic of Aref’s TOC; (iii) spheroid stained to reveal the presence of calcein AM (green); CD8 T cells (red); tumor cells (EpCAM; purple); and all nucleated cells (Hoechst; blue). Scale bars: 20 μm. (iv) Cell viability, and (v) cytokine expression profile over time in spheroids derived from patients and treated with different immunotherapies: α-PD-1: pembrolizumab, 250 μg mL−1); α -CTLA-4: (ipilimumab, 50 μg mL−1); or a combination. Taken from reference [48]. (d) TOC proposed by Bruce et al. [49] to recreate a bone marrow microenvironment and study acute lymphoblastic leukemia (ALL): (i) schematic representation, (ii) actual image, (iii) and detail of the post array within the device. (iv–vii) Confocal images of co-cultures of SUP-B15 (yellow arrows) and BMSC cells (white arrows) in (iv) 2D static, (v) 3D static, and (scale bars: 500 μm and 100 μm) (vi) 3D dynamic models. Proliferating cell nuclei were stained with Ki67 (green). Actin filaments were stained with phalloidin (red). Cell nuclei were stained with DAPI (blue). Scale bars: 20 μm. (vii) Chemoresistance of tumor cells to Ara-C among tri-culture or monoculture systems, in 2D versus 3D culture, and exposed (or not) to interstitial flow. (+) and (*) indicate significant difference between groups of p < 0.1, and p < 0.05, respectively. Taken from reference [49].](https://figures.cochat.ai/paper-figures/bf26efaa736246e18e74849343e0410f/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-6.jpg)
![Figure 7 Vascularized tumor-on-chip (TOC) systems. (a) A gelatin and hyaluronic acid (HA) construct, built in a PDMS device, traversed by an endothelialized microchannel. Taken from reference [54]; (b) TOC devised by Ozkan et al. [55]. (i) Schematic representation of a breast tumor microenvironment connected to a healthy liver niche. (ii) Close-up view of the TOC system. Confocal images show GFP-breast cancer cells (green) and particles circulating inside the vascular channel (red) and FITC-anti-albumin immunostained healthy liver cells (green) and particles circulating inside the vascular channel (red). Scale bar: 500 µm. (iii) CFD simulation showing the cross-sectional shear stress profiles in tumor and healthy vessels. Taken from reference [55]; (c) TOC by Shirure et al. [56]. (i) Schematic representation of the device, and (ii) confocal slice of the microvascular network (green) fabricated within the TOC central chamber and perfused with fluorescently labeled dextran (orange). Scale bar: 50 µm. Taken from reference [56]; (d) Bottom-up engineering of vascularized tumor models proposed in Agarwal et al. [57]. (i) Schematic representation of the strategy. (ii) Comparison of the effect of docetaxel, expressed as IC50, for three different microtumor models: 2D (black), a-vascular 3D (blue) and vascularized 3D (red) models; (*) indicate statistically significant difference of p < 0.05 when 3D vascularized models are compared to 2D culture model, and (#) significant differences of p < 0.05 when 3D vascularized models are compared with 2D and 3D avascular culture models. Taken from reference [57]. (e) Vascularized tumor-on-chip developed by Sobrino et al. [58]. (i) Scheme of the microfluidic device: a PDMS microfluidic chip composed of an array of three tissue chambers, each connected to two straight channels mimicking an arteriole (line of higher pressure) and the venule (line of lower pressure). Channels were also connected to the medium inlets and outlets. A hydrostatic pressure differential of 10 mm H2O was established to enable flow across the microfluidic channel, while a pressure gradient of 5 mm H2O was set across the tissue chambers to favor transport across the hydrogel. (ii) A human-endothelial cell vasculature net was fabricated within diamond-shaped tissue chambers containing EC-like matrix. Remarkably, the development of vasculature in these tissue chambers occurred spontaneously by self-assembly of EC cells initially seeded within the channels and the tissue chamber at day zero. Endothelial cells were continuously transduced with mCherry for easy visualization of the network (iii) Experiments of continuous perfusion of Dextran X show that the vascular network is practically leak-free after several days. (iv) Growth of tumors, fabricated by a spheroid formation method assisted by thrombin, seeded within the vasculature network models after 6, 8, 10, and 12 days of culture at continuous perfusion. (v) Different drugs were tested in this tumor-on-chip system; (vi and vii) the model correctly discriminates between drugs that target the tumor-vasculature formation capabilities and those that target the tumor. Scale bars: 50 µm. Taken from reference [58].](https://figures.cochat.ai/paper-figures/c1fbb9d2d8a445028c0bcc79d8928c86/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-7.jpg)
![Figure 8 Application scenarios for tumor-on-chip systems. (a) Fundamental studies [30,31,33,35,36,41,43,44,45,48,50,51,53,54,55,56,60,62,64,65,66,67,68,70,71,72,73,80,85,105,186,187,188,189,190,191,192,193]; (b) Pharmacological screening and testing [21,22,23,27,28,29,32,43,47,50,55,56,57,58,59,63,64,165,177,194]; and (c) personalized/precision medicine strategies [24,37,42,56,69,104,195,196,197,198].](https://figures.cochat.ai/paper-figures/311ce3dde0064969ab8ec026c7090291/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-8.jpg)
Verification
Claims the paper makes
103 Valid · 4 Not valid · 30 Not checked · 12 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“For example, when Pbase was higher than Ptip, an invasive phenotype was favored”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.2. Spheroids in a Hydrogel Matrix
What the sources say
- Disputedcites [30] Tien, 2016, Interstitial fluid pressure regulates collective invasion in engineered human breast tumors via Snail, vimentin, and Transition to invasion, Integr. Biol. sourceExperimental — accuracy not yet measured
The Results section reports the opposite: when Pbase>Ptip, none of 51 aggregates developed invasions. Invasion was promoted when Pbase<Ptip, with 50% of aggregates developing invasions. Page numbers were not provided in the supplied passages. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The penetration of NPs into the tissue was mainly influenced by their diameter (Figure 4a-iv–vi) and NP transport was predominantly dispersion-limited.”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.2. Spheroids in a Hydrogel Matrix
What the sources say
- Disputedcites [27] Albanese, 2013, Tumour-on-a-chip provides an optical window into nanoparticle tissue transport, Nat. Commun. sourceExperimental — accuracy not yet measured
The Results section (“Effect of flow rate on tissue accumulation”) says nanoparticles diffuse into spheroid tissue after accumulating at its surface; increased flow did not increase penetration depth. The claim says transport was predominantly dispersion-limited, whereas the paper describes diffusion as the mechanism of penetration. Its separate finding that diameter limits penetration is supported by the Results (“Effect of nanoparticle size on tissue accumulation”). (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Indeed, the 3D static and microfluidic models demonstrated coordinated cell-cell and cell-matrix interactions that were not detectable in the 2D static model.”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.4. Spheroids Surrounded by “Healthy” Tissues In some instances, tumor spheroids have been embedded in hydrogels containing normal (i.e., non-cancerous cells) within microfluidic chambers. For example, Aung et al. [50] developed a tumorous microtissue encapsulated by an endothelial barrier composed of HUVECs. The authors mixed breast cancer spheroids (MCF-7) into a suspension of HUVECs (~50 spheroids into 5 mL of a HUVEC suspension containing 0.4 × 105 cells/mL). This mix was centrifuged, and the pellet was suspended in 100 µL of 10% gelatin methacryloyl (GelMA); this new mixture was then loaded into thin microfluidic devices. Using a microscope, the authors located areas where cancer spheroids were surrounded by HUVECs and photocrosslinked these locations, flushing out the rest of the non-crosslinked hydrogel. This operation resulted in a hydrogel micro-cosmos containing spheroids surrounded by HUVEC cells. Over time, the HUVECs chemotactically migrated from the bulk of the hydrogel towards its perimeter and spontaneously developed an endothelial barrier around the GelMA construct (Figure 6a-i–iii). As a result, starting from homogeneity, the HUVEC density varied in different areas within the constructs over time (Figure 6a-iv). The size of the tumor spheroids, as determined by their projected area, also increased over time (Figure 6a-v). Thus, this tumor-on-chip produces tumor spheroids within a semisynthetic extracellular matrix embedded in a cell-monolayer endothelial barrier conformed by tight cell-cell E-cadherin junctions and encompassing the entire length of the GelMA hydrogel. This simple and smart platform was also used to evaluate the effect of DOX (Figure 6a-vi,vii). After 5 days of cultivation, they administered different doses of DOX (1, 10 and 100 µg/mL) for 3 days. Figure 6a-vi shows bright-field images of the HUVEC-MCF7 constructs before (top row) and 3 days after (bottom row) DOX treatment. Red arrows indicate the endothelial barrier. At concentrations of 10 and 100 μg/mL, DOX destroyed the endothelial barrier, decreased the size of spheroids, and caused a darkening of the MCF7 spheroids (Figure 6a-vii). Jeong et al. developed a tumor-on-chip to investigate the 3D interplay between cancer cells and fibroblasts (Figure 6b) [51]. This tumor-on-chip system consisted of four units; each unit comprised seven channels, each one 1000 μm wide and 190 μm deep (Figure 6b-i–iv). Channels 2, 6, and 4 were designated for non-cancer or cancer cell culture, and channels 1, 3, 5, and 7 were used for medium filling (Figure 6b-iii). The device was designed for intermittent feeding and the cell culture medium was changed every day. A collagen I solution (2 mg/mL) was mixed with the cells before being loaded into the device channels. Mono- and co-cultures of HT29 cancer cells and normal fibroblasts (CCD-18Co) were performed (Figure 6b-v) and, in some experiments, naïve collagen I (without cells) was loaded in the different channels of the device. A crosstalk between the cancer cells and fibroblasts was observed. After 5 days, the HT-29 cells formed viable spheroids and their growth was stimulated by co-culture with fibroblasts (Figure 6b-v). Increased expression of α-SMA and enhanced migration activity suggested fibroblast activation. The authors also observed changes in the expression of intracellular proteins related to angiogenesis and apoptosis. For instance, CD26, GM-CSF, SerpinE1, TIMP-1, HB-EGF, TSP-1, and GDNF were up-regulated and phospho-p53 (S15), phospho-p53 (S46), phospho-p53 (S392), pro-caspase-3, and cytochrome C were down-regulated in the tumor spheroids in co-culture. The spheroids co-cultured with fibroblasts exhibited increased expression of fibronectin, along with reduced expression of Ki-67. The effects of DOX and paclitaxel were also evaluated in this platform. Co-cultured spheroids also exhibited lower levels of DOX uptake and reduced sensitivity to paclitaxel (Figure 6b-vii). This 3D co-culture platform enabled the study of tumor microenvironment factors related to the epithelial-mesenchymal transition process, fibroblast activation, and drug resistance. Aref et al. conducted experiments in a commercial DAX-1 microfluidic system (Aim Biotech) in which patient-derived spheroids (PDOSTS) were cultured in contact with immune system cells to recreate the tumor immune microenvironment and screen the response of tumors to immunotherapy (therapies based on antibodies) [48]. Tumor biopsies from patients were mechanically and enzymatically dissociated to yield spheroids, cell agglomerates, and single cells (Figure 6c-i). The spheroids were separated for culture in the DAX-1 microfluidic device (Figure 6b). The DAX-1 chip was composed of three microfluidic chambers—a central gel channel surrounded by two channels for media circulation (Figure 6c-ii). The PDOSTS spheroids (40–100 μm in diameter) were embedded in collagen type I hydrogels in the central chamber and cultured. In the side channels, medium with or without monoclonal antibodies was circulated. The authors demonstrated the presence of autologous tumor-infiltrating immune cells (CD8-T) (Figure 6c-iii). Treatment with an anti-PD-1 antibody showed cancer cell death mediated by CD8 T-cells. Analysis of cytokines (Figure 6c-iv,v) revealed a natural evolution of cytokine and growth factor secretion over time (e.g., IL-8 VEGF, IL-12, CCL4). This study demonstrated that patient-derived tumor spheroids retain lymphoid and myeloid subsets of immune cells and that those cell populations could be further cultured in microfluidic chips. Bruce et al. studied acute lymphoblastic leukemia (ALL) in a 3D microfluidic system (Figure 6d) [49]. The device consisted of four perfusion microchannels. Chip dimensions were set considering the nutrient diffusion limits (i.e., relevant diffusional length scales) and aimed to recreate the interplay between the different cell types involved in ALL (Figure 6d-i,ii). Cell loading and culture medium feeding was performed through two ports (“cell in” and “media in”) placed at the inlet side of the device. SUP-B15 leukemic cells were cultured in the presence or absence of human bone marrow stromal cells (BMSCs) and human osteoblasts (HOBs). Cells were suspended in medium with 88% collagen type I—a concentration that is consistent with the stiffness of bone marrow (< 300 Pa). After collagen I gelation, culture medium was fed through the inlet and into the microchannels. Velocity profiles within the microchannels, set to be similar to that in the interstitial space of the bone marrow, were maintained at 0.27 ± 0.18 μm/s. Cell culture was performed in 2D static, 3D static, and 3D microfluidic models (Figure 6d-iv–vi), and significant differences in cell morphology and expression were found. The authors used this microfluidic platform to evaluate cell-cell and cell-matrix interplay in a controlled microenvironment that recapitulated physiological ranges of critical dynamical variables. Indeed, the 3D static and microfluidic models demonstrated coordinated cell-cell and cell-matrix interactions that were not detectable in the 2D static model. The 3D platform proved to be a more accurate bone marrow niche model, where different cells in culture (leukemic cells, human bone marrow stromal cells, and human osteoblasts) could interact in a dynamic fashion. In addition, chemoresistance studies were carried out by exposing 2D and 3D cultures to cytarabine (Ara-C), and the bone marrow microenvironment was found to have a protective role in cancer cell survival during treatment. Moreover, a lower chemotherapeutic sensitivity of leukemic cells was observed in the 3D tri-culture models than in the 2D models (Figure 6d-vii,viii). The 3D microfluidic model developed in this work is a suitable in vitro option for the study of tumor cell biology in the bone marrow niche (i.e., the space where the leukemic disease is initiated) and the site of metastatic malignancies characterized by high anticancer drug resistance.
What the sources say
- Disputedcites [49] Bruce, A., Evans, R., Mezan, R., Shi, L., Moses, B.S., Martin, K.H., Gibson, L.F., and Yang, Y. (2015). Three-Dimensional Microfluidic Tri-Culture Model of the Bone Marrow Microenvironment for Study of Acute Lymphoblastic Leukemia. PLoS ONE, 10. sourceExperimental — accuracy not yet measured
In Results and Discussion, “Cell-Cell Interactions” (page not supplied), the paper says direct cell-cell interactions were visible in the 2-D static model, contrary to the claim that they were not detectable there. It also says the 3-D static model lacked interaction without dynamic stresses. The paper favors the 3-D microfluidic model as a more authentic niche, but not the claimed contrast across all three models. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition to their remarkable internal heterogeneity, the tumor stromal tissues (i.e., the tissues surrounding the tumor), act as a dynamic source (and reservoir) of various cytokines and growth factors that influence tumor progression and pharmacological responses [19].”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 2. The Tumor Niche
What the sources say
- Supportedcites [19] Han, 2016, Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip, Cancer Lett. source
The Introduction describes stromal tissue as a repository for growth factors and cytokines that influence tumor growth and drug response. Section 2 also describes stromal-associated cells producing cytokines and links the resulting chemical environment to tumor progression and therapeutic resistance. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, organ-on-chip systems—microphysiological systems that combine the use of microfluidics, tissue engineering, and microfabrication tools—have shown promise sustaining functional microtissues for relatively extended timeframes [9,10,11,12].”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [9] Zheng, 2016, Organ-on-a-Chip Systems: Microengineering to Biomimic Living Systems, Small source
- Partly supportedcites [10] Esch, 2015, Organs-on-chips at the frontiers of drug discovery, Nat. Rev. Drug Discov. sourceExperimental — accuracy not yet measured
The ‘Comparison with conventional models’ section says organs-on-chips can reconstitute organ-level physiological functions, supporting the functional-microtissue part of the claim. But the passages do not establish that this function is sustained for relatively extended periods; ‘Current challenges and limitations’ instead describes long-term culture as a major challenge. Page numbers are not available in our copy. (LLM, conf=0.84)
- Supportedcites [11] Trujillo-de Santiago, G., Lobo-Zegers, M.J., Montes-Fonseca, S.L., Zhang, Y.S., and Alvarez, M.M. (2018). Gut-microbiota-on-a-chip: An enabling field for physiological research. Microphysiol. Syst., 2. source
The “Microbiota-related studies in gut-on-chip systems” section (page unavailable) describes Caco-2 cells cultured for one week in a gut-on-chip model and reports tests of epithelial barrier integrity. It also reports that a Caco-2 monolayer remained viable during 48 hours of exposure to bacterial biofilm products, supporting the hedged claim that such systems show promise for sustaining functional tissue models over extended periods. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [12] Zhang, 2017, Organ-on-a-chip devices advance to market, Lab Chip source
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
100 more claims · 74 with their cited sources checked
Create a free account to see all 149 claims and to verify the 11 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 10
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These systems enable continuous delivery of oxygen, nutrients, and therapeutic agents while introducing shear stress and directional mass transport, thereby allowing the investigation of flow-regulated processes within a tumor-relevant architecture [224,225,226,227,228].”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [225]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.3. Non-Spheroid Models where 3D Cancer Tissues are in Contact with Non-Cancerous Tissues
“The HMFs and MCF10-DCIS cells established a crosstalk at the interface between the cancerous and normal microtissue sections.”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.3. Non-Spheroid Models where 3D Cancer Tissues are in Contact with Non-Cancerous Tissues
“The change in shape of MCF710-DCIS cells, and their ability to remodel the matrix, suggested the onset of a DCIS to IDS transition.”
Citations
Cites
Items 201–229 of 229
Guo, W. M., Loh, X. J., Tan, E. Y., Loo, S. C. J., & Ho, V. H. B. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5000604 · Cited by 40 · cited 1×
“Other scaffold-free methods have been recently reported—for example, the force-driven formation of spheroids by dielectrophoresis using interdigitated microelectrodes [139], the use of acoustic bulk and surface waves [140,141], and the magnetically assisted fabrication of spheroids labeled with paramagnetic particles…”
MethodCarr, S. D., Green, V. L., Stafford, N. D., & Greenman, J. (2013) · Otolaryngology · doi:10.1177/0194599813507427 · Cited by 40
Lara, R. P., & Álvarez, M. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130118 · Cited by 39
Self-citationMaintenance of Head and Neck Tumor On-Chip: Gateway to Personalized Treatment?
Bower, R., Green, V. L., Kuvshinova, E., Kuvshinov, D., Karsai, L., Crank, S. T., Stafford, N. D., & Greenman, J. (2017) · Future Science OA · doi:10.4155/fsoa-2016-0089 · Cited by 38 · cited 2×
“have described an experiment in which they were able to sustain the viability of head and neck cancerous tissue for 48 h in a simple microfluidic chamber [197].”
BackgroundYuan, T., Gao, D., Li, S., & Jiang, Y. (2018) · Chinese Chemical Letters · doi:10.1016/j.cclet.2018.07.013 · Cited by 37 · cited 1×
“Nevertheless, recent papers illustrate the use of naturally derived hydrogels for spheroid fabrication, such as collagen [122,162], Matrigel [142,143], alginate [146], and hyaluronic acid [163], and combinations of these and other materials [134,164].”
BackgroundSacrificial Bioprinting of a Mammary Ductal Carcinoma Model
Duchamp, M., Liu, T., van Genderen, A. M., Kappings, V., Oklu, R., Ellisen, L. W., & Zhang, Y. S. (2019) · Biotechnology Journal · doi:10.1002/biot.201700703 · Cited by 37
Self-citationGarza-García, L. D., García‐López, E., Camacho-León, S., Rocha-Pizaña, M. D. R., López‐Pacheco, F., López-Meza, J., Araíz-Hernández, D., Tapia-Mejía, E. J., Santiago, G. T., Rodriguez, C. A., et al. (2014) · Lab on a Chip · doi:10.1039/c3lc51301g · Cited by 36 · cited 1×
“Several other papers have illustrated the use of CFD to improve the hydraulic design of lab-on-chip systems [221] and organ-on-chip systems [69,222], including tumor-on-chip devices.”
BackgroundSelf-citationGeneration of 3-D glioblastoma-vascular niche using 3-D bioprinting
Lee, V. K., Dai, G., Zou, H., & Yoo, S.-S. (2015) · 2015 41st Annual Northeast Biomedical Engineering Conference (NEBEC) · doi:10.1109/nebec.2015.7117111 · Cited by 35 · cited 1×
“In particular, 3D bioprinting will be also a valuable asset [208,209].”
BackgroundMicrofluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment
Holton, A. B., Sinatra, F. L., Kreahling, J., Conway, A. J., Landis, D. A., & Altiok, S. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169797 · Cited by 35
Formation of multilayer aggregates of mammalian cells by dielectrophoresis
Sebastian, A., Buckle, A.-M., & Markx, G. H. (2006) · Journal of Micromechanics and Microengineering · doi:10.1088/0960-1317/16/9/003 · Cited by 34 · cited 1×
“Other scaffold-free methods have been recently reported—for example, the force-driven formation of spheroids by dielectrophoresis using interdigitated microelectrodes [139], the use of acoustic bulk and surface waves [140,141], and the magnetically assisted fabrication of spheroids labeled with paramagnetic particles…”
MethodDevelopment of a three-dimensional microfluidic system for long-term tumor spheroid culture
Kwapiszewska, K., Kwapiszewski, R., Stelmachowska, A., Chudy, M., Dybko, A., & Brzózka, Z. (2012) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2012.07.045 · Cited by 34
Durymanov, M., Kroll, C., Permyakova, A., O'Neill, E., Sulaiman, R., Person, M., & Reineke, J. (2019) · Translational Oncology · doi:10.1016/j.tranon.2018.10.003 · Cited by 34
The ethics of animal research: a survey of the public and scientists in North America
Joffe, A. R., Bara, M., Anton, N., & Nobis, N. (2016) · BMC Medical Ethics · doi:10.1186/s12910-016-0100-x · Cited by 33
Microfluidic co-culture devices to assess penetration of nanoparticles into cancer cell mass
Jarvis, M., Arnold, M., Ott, J., Pant, K., Prabhakarpandian, B., & Mitragotri, S. (2017) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10079 · Cited by 32 · cited 2×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
BackgroundGioeli, D., Snow, C. J., Simmers, M. B., Hoang, S. A., Figler, R. A., Allende, J. A., Roller, D. G., Parsons, J. T., Wulfkuhle, J. D., Petricoin, E. F., et al. (2019) · Lab on a Chip · doi:10.1039/c8lc00755a · Cited by 31
Chen, Y.-Q., Kuo, J.-C., Wei, M.-T., Chen, Y.-C., Yang, M.-H., & Chiou, A. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.11.046 · Cited by 29 · cited 1×
“Nevertheless, recent papers illustrate the use of naturally derived hydrogels for spheroid fabrication, such as collagen [122,162], Matrigel [142,143], alginate [146], and hyaluronic acid [163], and combinations of these and other materials [134,164].”
BackgroundTitles of chemical papers in British and foreign journals
(1850) · Quarterly Journal of the Chemical Society of London · doi:10.1039/qj8500200367 · Cited by 25
Interaction between lung cancer cell and myofibroblast influenced by cyclic tensile strain
Huang, J.-W., Pan, H.-J., Yao, W.-Y., Tsao, Y.-W., Liao, W.-Y., Wu, C.-W., Tung, Y.-C., & Lee, C.-H. (2013) · Lab on a Chip · doi:10.1039/c2lc41050h · Cited by 24
Regier, M. C., Maccoux, L. J., Weinberger, E. M., Regehr, K. J., Berry, S. M., Beebe, D. J., & Alarid, E. T. (2016) · Biomedical Microdevices · doi:10.1007/s10544-016-0083-x · Cited by 23
Park, S. M., Lee, S. J., Lim, J., Kim, B. C., Han, S. J., & Kim, D. S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b15821 · Cited by 22 · cited 1×
“Other materials have been confirmed as suitable non-adherent surfaces due to their topography [155] or high hydrophilicity.”
BackgroundMasterton, M., Renberg, T., & Kälvemark Sporrong, S. (2014) · BioSocieties · doi:10.1057/biosoc.2013.39 · Cited by 21
Fu, J., Zhou, Y., Shi, X., Kang, Y., Lu, Z. S., Li, Y., Li, C. M., & Yu, L. D. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.11.038 · Cited by 21 · cited 1×
“For example, the commercially available Ultra Low Attachment (ULA) microwell culture plates have become a popular resource for fabricating spheroids [20,126,156], as has hydrophilic filter paper, which enables the spontaneous formation of prostate cancer spheroids and a significant enrichment of the cancer stem cell (…”
MethodHao, Y., Zhang, L., He, J., Guo, Z., Ying, L., Xu, Z., Zhang, J., Lu, J., & Wang, Q. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061754 · Cited by 20
A lab-on-a-chip device for investigating the fusion process of olfactory ensheathing cell spheroids
Munaz, A., Vadivelu, R. K., John, J. A. S., & Nguyen, N.-T. (2016) · Lab on a Chip · doi:10.1039/c6lc00815a · Cited by 20 · cited 1×
“Several other papers have illustrated the use of CFD to improve the hydraulic design of lab-on-chip systems [221] and organ-on-chip systems [69,222], including tumor-on-chip devices.”
BackgroundFinding the tumor copycat: Approximating a human cancer
Van Dyke, T. (2010) · Nature Medicine · doi:10.1038/nm0910-976 · Cited by 19 · cited 2×
“Today, less than 10% of the anticancer drugs that enter clinical trials ever reach the market [7,8].”
BackgroundLim, W., & Park, S. (2018) · Preprints.org · doi:10.20944/preprints201811.0608.v1 · Cited by 19
Sylvester, D., M. Hattersley, S., D. Stafford, N., J. Haswell, S., & Greenman, J. (2013) · Current Analytical Chemistry · doi:10.2174/157341113804486446 · Cited by 10
Cha, J., & Kim, P. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.018 · Cited by 8
Erdoğan, Ö. Ş., Kılıç, S., Bılır, A., et al. (2019) · BioMed Research International · doi:10.1155/2019/1407167 · Cited by 7
Cited by
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
Organoid and Spheroid Tumor Models: Techniques and Applications
Gunti, S., Hoke, A. T. K., Vu, K. P., & London, N. R. (2021) · Cancers · doi:10.3390/cancers13040874 · Cited by 479
“However, a majority of these studies utilized cancer cell lines to co str ct s eroi s a o ly fe studies used patient-derived tumor tissue [74].”
BackgroundA role for microfluidic systems in precision medicine
Ayuso, J. M., Virumbrales-Muñoz, M., Lang, J. M., & Beebe, D. J. (2022) · Nature Communications · doi:10.1038/s41467-022-30384-7 · Cited by 216
Neufeld, L., Yeini, E., Reisman, N., Shtilerman, Y., Ben-Shushan, D., Pozzi, S., Madi, A., Tiram, G., Eldar-Boock, A., Ferber, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi9119 · Cited by 189
Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology
Osuna de la Peña, D., Trabulo, S. M. D., Collin, E., Liu, Y., Sharma, S., Tatari, M., Behrens, D., Erkan, M., Lawlor, R. T., Scarpa, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25921-9 · Cited by 138
Metadata
- Authors
- Trujillo-de Santiago, G., Flores-Garza, B. G., Tavares-Negrete, J. A., Lara-Mayorga, I. M., González-Gamboa, I., Zhang, Y. S., Rojas-Martínez, A., Ortiz-López, R., & Álvarez, M. M.
- Affiliations
- Centro de Biotecnología-FEMSA, Tecnologico de Monterrey, Monterrey, Nuevo León CP 64849, Mexico
- Tecnológico de Monterrey (MX)
- Brigham and Women's Hospital (US)
- Centro de Investigación y Transferencia en Salud, Hospital San José, Tecnologico de Monterrey, Monterrey, Nuevo León CP 64849, Mexico
- Corresponding author
- Álvarez, Mario Moisés
- ORCID
- Venue
- Materials
- Publisher
- MDPI AG
- Published
- 2019-09-11
- Volume
- 12
- Issue
- 18
- Pages
- 2945
- ISSN
- 1996-1944 (ISSN-L)
- PMC
- PMC6766252
- OpenAlex
- W2972592345
- Cited by
- 184
- References
- 231
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 47 · 2023: 21 · 2022: 25 · 2021: 47 · 2020: 13 · 2019: 2
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Materials (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Consejo Nacional de Ciencia y Tecnología (SNI256730, SNI 26048)
- Tecnologico de Monterrey (002EI CIN01)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor-on-a-chip, microfluidics, solid tumors, tumor microenvironment, 3D tumor culture, anticancer drug screening, precision oncology, 3D bioprinting, computational fluid dynamics, high-throughput omics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.